Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received market approval from the National Medical Products Administration (NMPA) for its biosimilar version of Novo Nordisk’s (NYSE: NVO) GLP-1 receptor agonist Victoza (liraglutide), which is indicated for blood sugar control in type 2 diabetes patients.
Liraglutide, with a 97% sequence homology with human GLP-1, is primarily used to enhance blood sugar control in adults with type 2 diabetes. Huadong Medicine’s biosimilar version is noted as the first biosimilar approval in China, following the originator drug from Novo Nordisk.- Flcube.com
